BioTOP Berlin-Brandenburg BioTOP Berlin Brandenburg is the central contact and coordination office for all issues concerning biotechnology in the German capital region. It is our objective to coordinate all regional activities in biotechnology by networking with all key players and to initiate specific projects in order to turn Berlin-Brandenburg into a globally leading life science cluster. The services provided by BioTOP include: For more information, including a database with comprehensive profiles of all companies and scientific work groups, please visit our website at www.biotop.de. Address: |
 |
Business Wire Business Wire is a trusted partner to hundreds of Health, Medical, Biotech and Pharmaceutical companies and organizations throughout the world, delivering more corporate news releases from more sources to more destinations than any other service. Business Wire's news wire circuits enable you to target your news to select audiences based on your geographic and industry market needs. In fact, Business Wire's delivery network is composed of some 60 news agencies, financial and information providers and web-based news services around the globe. From delivery to audiences in a single city to comprehensive worldwide coverage including translations, Business Wire offers you an easy, one-stop solution. For additional information email tradeshow@businesswire.com or visit www.businesswire.com |
 |
Citigate Dewe Rogerson Citigate Dewe Rogerson is the leading international consultancy specialising exclusively in financial and corporate communications across the UK, Europe, North America and Asia. Citigate has a dedicated Pharma & Biotech team with more than 60 years combined experience in the sector and a unique mix of skills: corporate and financial PR and investor relations, finance, journalism and academic science. The team provides sector expertise and forms an integrated part of Citigate Dewe Rogerson, benefiting from the company’s overall strength and from the cross-fertilisation of ideas across sectors. The Citigate Pharma & Biotech team has an established track record in working with biotechnology companies at all stages in development. As well as core skills in financial calendar work, transactions support, financial PR and media relations, the team has extensive experience in branding, design and new media consultancy. Recent clients include global top-five biotechs, listed companies in the UK and Europe, and numerous emerging businesses in the UK, France, Germany, the Netherlands, and Scandinavia. Citigate’s Pharma & Biotech team has been involved in major corporate transactions such as IPOs, other public and private fundraisings, and M&As. We have advised on a number of IPO transactions across Europe including; METabolic EXplorer (Euronext Paris - €52 million), Algeta (Oslo Stock Exchange - €30 million), Santhera Pharmaceuticals (SWX – CH88.5 million), ThromboGenics (Euronext Brussels - €35 million), Hutchison China MediTech (AIM - £40 million), Zentiva (LSE and PSE – US $211 million), Arpida (SWX - €63 million), Inion (LSE - £35 million), TopoTarget (CSE - €30 million), BioFusion (AIM - £8.2 million) and ExonHit (Alternext - 7.3 million). |
 |
College Hill College Hill Life Sciences provides a full service communications consultancy focused on science-based sectors. Within the life science field we have established a leadership position by working in partnership with our clients to deliver high quality communications that build corporate value and promote leading edge products, technologies and services). |
 |
Financial Dynamics FD Life Sciences Team FD’s life sciences team has established a market leading practice and now represents over 90 companies worldwide. Clients range from the largest global players through to a large number of smaller fast growing businesses. In recent years, FD has been involved in some of the most significant M&A deals in the sector – working on the GE/Amersham, Nycomed/Altana, Shire/TKT transactions as well as over 30 IPOs in continental Europe, London and New York. With the team’s integrated approach to communications, we work closely with clients on all aspects of their communications programmes both developing and implementing strategy, as well as the day–to-day activities. With a combined staff of more than 20 in the life sciences teams in London and New York (including ex bankers, lawyers and journalists) FD’s team has unrivalled expertise and experience in the global healthcare market. It is this which continues to attract significant new business to FD. |
 |
Going Public Media AG Founded in1998 GoingPublic Media AG is today one of the leading publishers of magazines on technology trends, corporate finance and capital markets. 70-80 magazines, newsletters and books are being edited, printed and distributed each year. In addition to the monthly issued “GoingPublic Magazin” and its well known yearly special editions like “Corporate Finance & Private Equity Guide” or “Biotechnology” which are largely meant as reference books, the company publishes the likewise monthly “VentureCapital Magazin” (www.venturecapital.de). It stands as a hub for the private equity and venture capital industry in German speaking Europe and addresses investors and entrepreneurs who focus on trends in technology, corporate financing and venture capital/private equity. Special topics are additionally treated in supplements and special editions (“Tech-Guide”, “Start-up” a.o.). Since 2003, GoingPublic Media AG addresses retail investors via its subsidiary Smart Investor Media GmbH and the monthly issued magazine Smart Investor. The quarterly published “HV Magazin” focuses on organizational, technical und legal trends concerning the annual shareholder meeting and is directed to the responsibles of listed companies (CFOs, investor relations managers etc.). New in 2007 is “Unternehmeredition”, which focuses quarterly on Small and Medium-sized Business Entrepreneurs. Furthermore GoingPublic Media operates the corporate publishing division GoingPublic Services. About 10 magazines and newsletters are annually distributed on behalf of well-known venture capital companies and financial institutions. Since November 2006 GoingPublic Media is listed in the open market of Frankfurt stock exchange. The complete prospectus can be found at www.goingpublic.de/ir. All publications are published in German. Contact: Markus Rieger, CEO Websites: www.goingpublic.de, www.vc-magazin.de, www.hv-magazin.de, www.smartinvestor.de, www.unternehmeredition.de |
Medical Device Developments Medical Device Developments serves a growing international device industry now valued at over $160bn. Each edition boasts a line-up of leading industry professionals covering the major themes and addressing the key issues currently shaping the market. The publication is supported online by medicaldevice-network.com, a site used by the industry as a daily reference point covering current opinion and the latest developments as well providing a platform from which manufacturers can source suppliers and establish long-term supply partnerships. For more details please visit medicaldevice-network.com |
 |
Objective Capital Objective Capital is an independent provider of corporate investment research. Our clients are companies, or their advisors, that are either private, publicly listed, or in the process of preparing for listing. Objective’s life sciences research, produced regularly, and disseminated widely is an essential investment and communications tool. Sponsoring research is the most effective way for a company to build the strategic relationship it needs with the market to access investment funds, potential partners and ensure market interest in its stock. It also sends a strong message to potential investors that the company is committed to an open and transparent relationship with the market and ensuring that there will be a regular flow of investment research available. Readers of our research include individuals, professional investors, fund managers, family offices and corporations, who have a private or professional interest in being informed about life science opportunities. For more information please contact: |
 |
Pharmalicensing Pharmalicensing is the premier biopharmaceutical Open Innovation resource designed for professionals involved with partnering, licensing and business development worldwide. Actively supporting in- and out-licensing activities, Pharmalicensing provides partnering services, business development reports, industry news and a jobs source for candidates and employers. Pharmalicensing is used by over 90,000 users per month and is a division of UTEK Corporation. Visit www.pharmalicensing.com |
 |